Stage N2/IIIA non small cell lung cancer: An evidence-based review

Christopher B. Komanapalli, Charles Thomas, Mithran S. Sukumar

Research output: Contribution to journalReview articlepeer-review


Introduction: The N2 /IIIA Non small cell Lung cancer is a heterogenous group of patients with many differences within the stage that warrant different treatment strategies and have an individual prognosis that varies depending on the size, site and number of lymph node stations involved. Method: Review of the pertinent current literature on the identification of the various subsets of N2 disease and their management and prognosis. Discussion: Define the spectrum of N2 disease and characterize the subsets within the stage. Highlight the different management strategies and prognosis of the various N2 scenarios that are commonly seen. Examine the evidence for restaging after neoadjuvant therapy and the modalities that may be used. Summary: A concise outline of the subjects within the N2/IIIA stage with their evidence based treatment and survival.

Original languageEnglish (US)
Pages (from-to)127-139
Number of pages13
JournalCurrent Cancer Therapy Reviews
Issue number2
StatePublished - May 2007


  • Computed tomography scanning
  • Endoscopic ultrasound
  • Ipsilateral mediastinal lymph node
  • N2 Disease
  • Platinum-based therapy
  • Positron emission tomography

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research


Dive into the research topics of 'Stage N2/IIIA non small cell lung cancer: An evidence-based review'. Together they form a unique fingerprint.

Cite this